Brief: Siren Biotechnology And Catalent Enter Partnership For Manufacturing Of AAV Gene Therapies For Cancer
08/05/2024 16:05
May 8 (Reuters) - SIREN BIOTECHNOLOGY:
* SIREN BIOTECHNOLOGY AND CATALENT ENTER PARTNERSHIP FOR
MANUFACTURING OF AAV GENE THERAPIES FOR CANCER
* SIREN BIOTECHNOLOGY: CATALENT TO PROVIDE PROCESS
DEVELOPMENT,CGMP MANUFACTURING OF CO'S AAV VECTOR-BASED
THERAPEUTIC CANDIDATES FOR CLINICAL TRIAL USE
Source text for Eikon: ID:nGNX20qxWJ
Recent news on Catalent
See all newsBrief: Novo Holdings Completes Acquisition Of Catalent
Novo Nordisk rises as Catalent deal in US nears
Regulatory conditions on Novo Holdings' $16.5 bln Catalent deal fulfilled, companies say
Brief: Catalent And Novo Holdings Fulfill All Regulatory Closing Conditions For Pending Transaction
Brief: Novo Nordisk Says All Regulatory Closing Conditions Relating To Review Of Novo Holdings A/S's Pending Acquisition Of Catalent Have Been Fulfilled